Evidence
Heliyon. 2024 Apr 25;10(9):e30387. doi: 10.1016/j.heliyon.2024.e30387. eCollection 2024 May 15.
ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) has become one of the most frequent chronic liver diseases worldwide in recent decades. Metabolic diseases like excessive blood glucose, central obesity, dyslipidemia, hypertension, and liver function abnormalities cause NAFLD. NAFLD significantly increases the likelihood of liver cancer, heart disease, and mortality, making it a leading cause of liver transplants. Non-alcoholic steatohepatitis (NASH) is a more advanced form of the disease that causes scarring and inflammation of the liver over time and can ultimately result in cirrhosis and hepatocellular carcinoma. In this review, we briefly discuss NAFLD’s pathogenic mechanisms, their progression into NASH and afterward to NASH-related cirrhosis. It also covers disease epidemiology, metabolic mechanisms, glucose and lipid metabolism in the liver, macrophage dysfunction, bile acid toxicity, and liver stellate cell stimulation. Additionally, we consider the contribution of intestinal microbiota, genetics, epigenetics, and ecological factors to fibrosis progression and hepatocellular carcinoma risk in NAFLD and NASH patients.
PMID:38737288 | PMC:PMC11088336 | DOI:10.1016/j.heliyon.2024.e30387
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- Exerkines: Benign adaptation for exercise and benefits for non-alcoholic fatty liver disease
- Targeting hepatic macrophages for non-alcoholic fatty liver disease therapy
- Western Diet-Induced Nonalcoholic Fatty Liver Disease Mice Mimic the Key Transcriptomic Signatures Observed in Humans
- Liver Fatty Acid-binding Protein Is a More Reliable Biomarker for Liver Injury in Nonalcoholic Steatohepatitis than Other Etiologies of Hepatitis
- Chiglitazar attenuates high-fat diet-induced nonalcoholic fatty liver disease by modulating multiple pathways in mice
- A preclinical model of severe NASH-like liver injury by chronic administration of a high-fat and high-sucrose diet in mice
- Targeting cell death in NAFLD: mechanisms and targeted therapies
- Vaccinium spp. Berries in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease: A Comprehensive Update of Preclinical and Clinical Research
- Vaccinium spp. Berries in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease: A Comprehensive Update of Preclinical and Clinical Research
- Role of HSP90 in Type 2 Diabetes Mellitus and Its Association with Liver Diseases
- Prevalence of nonalcoholic fatty liver disease in Pakistan: a systematic review and meta-analysis
- Prevalence of nonalcoholic fatty liver disease in Pakistan: a systematic review and meta-analysis
- Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease
- NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review
- Gut microbiota metabolite trimethylamine N-oxide promoted NAFLD progression by exacerbating intestinal barrier disruption and intrahepatic cellular imbalance
- Analysis of machine learning based integration to identify the crosslink between inflammation and immune response in non-alcoholic fatty liver disease through bioinformatic analysis
- Adaptation of Clinical Practice Guideline for Assessment of Liver Fibrosis in Patients with Non Alcoholic Fatty Liver Disease in Isfahan Province
- Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact
- Effects of Marine Natural Products on Liver Diseases
- Polysaccharide of Atractylodes macrocephala Koidz alleviates NAFLD-induced hepatic inflammation in mice by modulating the TLR4/MyD88/NF-κB pathway
- Polysaccharide of Atractylodes macrocephala Koidz alleviates NAFLD-induced hepatic inflammation in mice by modulating the TLR4/MyD88/NF-κB pathway
- Association between nonalcoholic steatohepatitis and high serum ferritin levels in type 2 diabetes mellitus
- Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes
- Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes
- GA receptor targeted chitosan oligosaccharide polymer nanoparticles improve non-alcoholic fatty liver disease by inhibiting ferroptosis
- Medaka liver developed Human NAFLD-NASH transcriptional signatures in response to ancestral bisphenol A exposure
- Natural history and progression of metabolic dysfunction-associated steatotic liver disease
- Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia
- Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia
- Intricate interplay between cell metabolism and necroptosis regulation in metabolic dysfunction-associated steatotic liver disease: A narrative review
- Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities
- Excess cardiovascular mortality in men with non-alcoholic fatty liver disease: A cause for concern!
- From non-alcoholic fatty liver disease to metabolic-associated steatotic liver disease: Rationale and implications for the new terminology
- Unveiling the role of ferroptosis in the progression from NAFLD to NASH: recent advances in mechanistic understanding
- Hepatic miR-363 promotes non-alcoholic fatty liver disease by suppressing INSIG1
- Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review
- Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review
- Discovery of genomic loci for liver health and steatosis reveals overlap with glutathione redox genetics
- miR-33 deletion in hepatocytes attenuates NAFLD-NASH-HCC progression
- Incidence of Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH) in the Female Population of North Karnataka: A Cross-Sectional Study
- An novel effective and safe model for the diagnosis of nonalcoholic fatty liver disease in China: gene excavations, clinical validations, and mechanism elucidation
- Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives
- Association between non-alcoholic fatty liver disease and metabolic abnormalities in children with different weight statuses
- Exploring Fibrosis Pathophysiology in Lean and Obese Metabolic-Associated Fatty Liver Disease: An In-Depth Comparison
- The rs1862513 promoter variant of resistin gene influences susceptibility to nonalcoholic fatty liver disease
- Trimethylamine N-oxide Induces Non-alcoholic Fatty Liver Disease by Activating the PERK Signaling Pathway
- Trimethylamine N-oxide Induces Non-alcoholic Fatty Liver Disease by Activating the PERK Signaling Pathway
- Alcoholic Liver Disease in China: A Disease Influenced by Complex Social Factors That Should Not Be Neglected
- Evaluation of Google Search Trends for Liver Diseases in Europe
- Effects of Mao tea from Nankun Mountain on nonalcoholic fatty liver disease in mice
- The roles and potential mechanisms of plant polysaccharides in liver diseases: a review
- Therapeutic potential of palmitoleic acid in non-alcoholic fatty liver disease: Targeting ferroptosis and lipid metabolism disorders
- Expression of Vascular Adhesion Protein-1 and Thrombospondin-1 in Gingival Crevicular Fluid of Patients with Periodontitis and Non-Alcoholic Fatty Liver Disease
- Sesaminol alters phospholipid metabolism and alleviates obesity-induced NAFLD
- Triglyceride-glucose-alanine aminotransferase index: A noninvasive serum predictor for identifying the severity of pediatric nonalcoholic fatty liver disease
- The burden of non-alcoholic fatty liver disease in Australia: an analysis of Global Burden of Disease study from 1990 to 2019
- The effect of synbiotics on liver enzymes, obesity indices, blood pressure, lipid profile, and inflammation in patients with non-alcoholic fatty liver: a systematic review and meta-analysis of randomized controlled trials
- The effect of synbiotics on liver enzymes, obesity indices, blood pressure, lipid profile, and inflammation in patients with non-alcoholic fatty liver: a systematic review and meta-analysis of randomized controlled trials
- Targeting mitochondrial homeostasis in the treatment of non-alcoholic fatty liver disease: a review
- Paricalcitol attenuates oxidative stress and inflammatory response in the liver of NAFLD rats by regulating FOXO3a and NFκB acetylation
- Association between nonalcoholic fatty liver disease scores and chronic periodontitis: A retrospective cohort study
- Interaction of periodontal clinical indicators in metabolic syndrome and nonalcoholic fatty liver disease: Implications for preventive interventions
- Key regulators of hepatic stellate cell activation in alcohol liver Disease: A comprehensive review
- The role and mechanism of pyroptosis and potential therapeutic targets in non-alcoholic fatty liver disease (NAFLD)
Evidence Blueprint
From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Exerkines: Benign adaptation for exercise and benefits for non-alcoholic fatty liver disease
- Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
- Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease
- Anthocyanin: A Potential Phytochemical Candidate for the Amelioration of Non-Alcoholic Fatty Liver Disease
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Targeting hepatic macrophages for non-alcoholic fatty liver disease therapy
- Non-alcoholic fatty liver disease in women - Current knowledge and emerging concepts
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action
- The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH
- The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota
- Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment
- Pathophysiological Features of Rat Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- RNA modifications in the progression of liver diseases: from fatty liver to cancer
- RNA modifications in the progression of liver diseases: from fatty liver to cancer
- Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies
- Western Diet-Induced Nonalcoholic Fatty Liver Disease Mice Mimic the Key Transcriptomic Signatures Observed in Humans
- Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review
- Liver Fatty Acid-binding Protein Is a More Reliable Biomarker for Liver Injury in Nonalcoholic Steatohepatitis than Other Etiologies of Hepatitis
- Outcomes and risk factors for mortality in clostridioides difficile infection in patients with NAFLD and NASH
- Targeted platelet with hydrogen peroxide responsive behavior for non-alcoholic steatohepatitis detection
- Occult liver disease: a multinational perspective
- Chiglitazar attenuates high-fat diet-induced nonalcoholic fatty liver disease by modulating multiple pathways in mice
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Enhanced non-alcoholic fatty liver detection: Computed tomography scan image analysis and noise reduction with morphological dilation
- Atorvastatin on Treatment of Nonalcoholic Fatty Liver Disease Patients
- NLRP3 inflammasome in hepatic diseases: A pharmacological target
- The role of Sirtuin 2 in liver - An extensive and complex biological process
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- The Influence of Emodin Succinyl Ethyl Ester on Non-Alcoholic Steatohepatitis Induced by a Diet High in Fructose, Cholesterol, and Fat in Mice
- A preclinical model of severe NASH-like liver injury by chronic administration of a high-fat and high-sucrose diet in mice
- Non-alcoholic fatty liver disease and periodontal disease: A systematic review and meta-analysis of cross-sectional studies
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Corrected and republished from: Metabolic associated liver disease
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Targeting cell death in NAFLD: mechanisms and targeted therapies
- Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
- Challenges and Solutions in the Management of Hepatocellular Carcinoma Associated with Non-Alcoholic Fatty Liver Disease
- Vaccinium spp. Berries in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease: A Comprehensive Update of Preclinical and Clinical Research
- Vaccinium spp. Berries in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease: A Comprehensive Update of Preclinical and Clinical Research
- Prevalence of nonalcoholic fatty liver disease and liver cirrhosis in Chinese adults with type 2 diabetes mellitus
- Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Role of HSP90 in Type 2 Diabetes Mellitus and Its Association with Liver Diseases
- The therapeutic mechanisms and beneficial effects of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease: a systematic review
- Prevalence of nonalcoholic fatty liver disease in Pakistan: a systematic review and meta-analysis
- Prevalence of nonalcoholic fatty liver disease in Pakistan: a systematic review and meta-analysis
- Prevalence of portal vein thrombosis in non-alcoholic fatty liver disease: a meta-analysis of observational studies
- Diagnosis and Treatment of Liver Disease: Current Trends and Future Directions
- Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
- Recent insights into the pathogenesis and therapeutic targets of chronic liver diseases
- MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
- Navigating the Link Between Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis and Cardiometabolic Syndrome
- Bacteroides and NAFLD: pathophysiology and therapy
- Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis
- Semaglutide alters gut microbiota and improves NAFLD in db/db mice